Peptide stacks / GLOW

GLOW

A three-ingredient stack discussed for recovery and skin appearance.

The short version

Ingredients

Why people discuss it
Discussed as a recovery pairing with a copper peptide added for skin-focused goals. These are community claims, not demonstrated benefits of the finished combination.
What it is
BPC-157, TB-500 and GHK-Cu. “Stack” may mean separate products; “blend” may mean a fixed-ratio vial. Neither name guarantees the ratio or the exact TB-500 substance.
Biggest caution
Individual ingredient research does not establish combination safety. Topical GHK-Cu experience cannot validate an injectable blend, and adding ingredients adds unresolved questions.
Stack context
GLOW adds GHK-Cu to the BPC-157/TB-500 pair. KLOW adds KPV to that ingredient list. More ingredients do not establish greater benefit.

Dose and frequency reference

Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.

Source agreement describes reported practice, not clinical validation.

GLOW 5:1:1 blend — subcutaneous

Community reference · Not clinical guidance
Amount
About 1.667 mg GHK-Cu + 333 mcg BPC-157 + 333 mcg TB-500
Frequency
Once daily
Duration / phase
4 weeks on; reported 2–4 weeks off

Single-publisher example for this exact GHK-Cu/BPC-157/TB-500 ratio: about 2.333 mg total per administration. It does not establish efficacy or compatibility of the blend. TB-500 is given daily here, unlike intermittent standalone examples. Reference only; this does not establish safety, effectiveness or individual suitability.

Community source · reviewed 2026-09-27
Compare reported schedules

Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.

Evidence & sources · Component evidence only

Community references document claims and reported practices. They are not clinical evidence. Some references contain supplier promotions or market treatment; their commercial context is identified in the source label.

Browse all stacksBack to the peptide library